Business Description
Wuhan YZY Biopharma Co Ltd
ISIN : CNE1000063C4
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.35 | |||||
Equity-to-Asset | 0.19 | |||||
Debt-to-Equity | 2.42 | |||||
Debt-to-EBITDA | -0.66 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 0.01 | |||||
9-Day RSI | 0.54 | |||||
14-Day RSI | 2.96 | |||||
3-1 Month Momentum % | -20.54 | |||||
6-1 Month Momentum % | -33.29 | |||||
12-1 Month Momentum % | -42.18 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.24 | |||||
Quick Ratio | 1.21 | |||||
Cash Ratio | 0.95 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -3.78 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -206.61 | |||||
ROA % | -65.4 | |||||
ROIC % | -85.72 | |||||
ROC (Joel Greenblatt) % | -366.75 | |||||
ROCE % | -165.87 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 13.54 | |||||
Price-to-Tangible-Book | 13.54 | |||||
EV-to-EBIT | -3.53 | |||||
EV-to-EBITDA | -3.54 | |||||
EV-to-FCF | -4 | |||||
Price-to-Net-Current-Asset-Value | 8.81 | |||||
Earnings Yield (Greenblatt) % | -28.33 | |||||
FCF Yield % | -25.67 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Wuhan YZY Biopharma Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil HK$) | |||
EPS (TTM) (HK$) | -1.024 | ||
Beta | - | ||
3-Year Sharpe Ratio | - | ||
3-Year Sortino Ratio | - | ||
Volatility % | 33.47 | ||
14-Day RSI | 2.96 | ||
14-Day ATR (HK$) | 0.075921 | ||
20-Day SMA (HK$) | 4.28 | ||
12-1 Month Momentum % | -42.18 | ||
52-Week Range (HK$) | 3.65 - 9.06 | ||
Shares Outstanding (Mil) | 193.85 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Wuhan YZY Biopharma Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Wuhan YZY Biopharma Co Ltd Stock Events
Event | Date | Price (HK$) | ||
---|---|---|---|---|
No Event Data |
Wuhan YZY Biopharma Co Ltd Frequently Asked Questions
What is Wuhan YZY Biopharma Co Ltd(HKSE:02496)'s stock price today?
When is next earnings date of Wuhan YZY Biopharma Co Ltd(HKSE:02496)?
Does Wuhan YZY Biopharma Co Ltd(HKSE:02496) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |